The QualityStocks Daily Thursday, August 1st, 2019

Today's Top 3 Investment Newsletters

HotOTC (NAHD) +340.00%

QualityStocks (RZLT) +121.59%

MarketClub Analysis (MYGN) +54.46%

The QualityStocks Daily Stock List

Maverick Technology Solutions (MVRK)

Penny Stock Hub, Biz Journals, News to Watch, OTC.Watch, Research Pool, OTC Markets, InvestorsHub, Investors Hangout, Stockopedia, Stockhouse, Trading View, Wallet Investor, and GlobeNewswire reported previously on Maverick Technology Solutions (MVRK), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Maverick Technology Solutions is the manufacturer of the highly acclaimed ROSINBOMB™ line of extraction presses and technology. The Company has greater than three years operating history developing and producing the ROSINBOMB™ line of rosin presses and accessories for extracting organic concentrates. ROSINBOMB presses require no chemicals or additional hardware to operate. Maverick Technology Solutions has its corporate headquarters in Phoenix, Arizona.

ROSINBOMB presses are ‘plug and play’ out of the box. The technology utilizes granted patent and patent pending techniques to optimize extraction processes and allow the user the ability to easily produce naturally-extracted, organic concentrates. ROSINBOMB presses are manufactured to be the premier quality presses available today. The Company’s stainless steel, fully electric and patent-pending technology delivers 5,000+ lbs of pressure. The design is to ensure the highest possible yield.

Maverick’s extraction presses and related accessories, most notably the ROSINBOMB Rocket, have been met with critical acclaim. The year 2018 saw the Rocket being named a top ten product by Forbes, the “Best Portable Rosin Press” by Herb, and one of the “Top Holiday Gifts Over $200” by Leafly.

Recently, Maverick Technology Solutions announced the recent patent filing of its pioneering Flow Channel Technology™. This technology permits processors to now produce large volumes of solventless extracts solely using heat and pressure. The frictionless Flow Channel Technology™ is a significant jump forward in extract production at a fraction of the cost of existing solvent-based systems.

Mr. Ryan Mayer, Inventor and President of Maverick Technology Solutions, said, “By advancing forward the existing technology that has propelled ROSINBOMB to become the leader in solventless extract production, we were able to develop our Flow Channel Technology™ to make solvent free mass production a reality. This combined with the added advantage of removing the use of parchment and eliminating manual collecting from the equation, undoubtedly delivers the industry the preeminent solution to manufacturing the highest quality clean extracts at an unparalleled cost.”

This week, Maverick Technology Solutions announced the issuance of US Design Patent No. D854,064 S. This patent illustrates and validates ROSINBOMB’s inventive design and technical implementation that ensures the entire line of extraction presses are equal in elegance and functionality.

Maverick Technology Solutions (MVRK), closed Thursday's trading session at $1.535, up 6.2284%, on 100 volume with 1 trade. The average volume for the last 3 months is 1,260 and the stock's 52-week low/high is $0.150000005/$2.0999999.

chart

Veritas Farms, Inc. (VFRM)

Alpha Stock News, Investor Ideas, Street Insider, Direct Cannabis Network, Market Wire News, Market Screener, Technical420, Simply Wall St, Stockwatch, Last10k, and GlobeNewswire reported earlier on Veritas Farms, Inc. (VFRM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Veritas Farms, Inc. is a vertically integrated agribusiness listed on the OTC Markets Group’s OTCQB. It focuses on the production of full spectrum hemp oil products with naturally occurring cannabinoids. The company previously went by the name SanSal Wellness Holdings, Inc. It changed its name to Veritas Farms, Inc. in February of this year. Veritas Farms produces premier quality, full spectrum CBD (cannabidiol) products from its sustainable farm (140 acres) in Pueblo, Colorado. The Company is registered with the Colorado Department of Agriculture to grow industrial hemp.

Veritas Farms markets and sells products under its Veritas Farms™ brand. It manufactures private label products for several top distributors and retailers. Veritas Farms™ brand full spectrum hemp extract products include vegan capsules, tinctures, formulations for sublingual applications and infused edibles, lotions, salves, and oral syringes in an array of size formats and flavors.

Its CBD Tincture is a full spectrum CBD oil. It contains no additives, fillers, or GMOs. In addition, it is third party lab tested to ensure quality. It is 100 percent grown and manufactured in Colorado.

Veritas Farms’ full spectrum CBD Salve is formulated with all natural ingredients. It contains beneficial cannabinoids from 100 percent Colorado Hemp. Furthermore, it is made from advanced extraction techniques. The Company’s farm can grow roughly 200,000 plants. Indoors, Veritas hosts 13,000 square feet of climate-controlled greenhouses.

Veritas Farms employs drip irrigation. This ensures every plant gets suitable hydration and that the Company conserves the Rocky Mountain water it uses. Instead of growing from seeds, Veritas Farms always cultivate from mother plants.

This week, Veritas Farms announced that it is expanding its distribution partnership with Kroger Family of Stores into five new States and adding additional stores in existing States. The additional distribution extends the already sizable partnership to five new States, including Texas, Virginia, Georgia, Montana, and Utah and totaling greater than 400 new stores.

Also this week, the Company announced that its Veritas Farms™ products have reached and surpassed more than 4,500 points of retail distribution. Veritas Farms’ Q1 and Q2 efforts in chain retail resulted in numerous national chain retailers launching Veritas Farms™ products in their stores. Total chain retail distribution added during this quarter represents thousands of additional stores across greater than 12 States.

Veritas Farms, Inc. (VFRM), closed Thursday's trading session at $1.59, up 8.9041%, on 304,333 volume with 296 trades. The average volume for the last 3 months is 117,539 and the stock's 52-week low/high is $0.200000002/$1.83000004.

chart

Aurania Resources Ltd. (AUIAF)

Triple H Stocks, Junior Mining Network, Metals News, Finance Recorder, The Gold Telegraph, Northern Miner, Geology for Investors, Wallet Investor, Stockhouse, Gold Stock Data, TradingView, Investors Hangout, Market Screener, and Dividend Investor reported earlier on Aurania Resources Ltd. (AUIAF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

A junior mineral exploration company, Aurania Resources Ltd. engaged in the identification, evaluation, acquisition and exploration of mineral property interests. The Company’s emphasis is on precious metals and copper and its flagship asset, is The Lost Cities – Cutucu Project. This Project is in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador. OTCQB-listed, Aurania Resources has its corporate headquarters in Toronto, Ontario.

The Company also has properties in Canton Valais, Switzerland – Siviez (Uranium, Copper and Gold); Marécottes (Uranium); and Mont Chemin (Gold). All are 100 percent held through Aurania Resources’ wholly owned subsidiary AuroVallis SARL.

The Cordillera del Condor – the eastern foothills to the Andes in southeastern Ecuador – hosts a well-endowed mineral belt. It contains 26 million ounces (Moz) of gold and close to 40 billion pounds (Blbs) of copper in NI-43-101 resources held by varied companies. The Lost Cities – Cutucu Project lies along-trend of that mineral belt. Therefore, Aurania Resources’ exploration is centered on finding the same kinds of deposits that occur in the Cordillera del Condor.

Regarding the Switzerland Projects, Aurania Resources made formal application in 2015 to obtain new five-year permits for its Swiss projects. The Company was advised that the Canton Authority (the Ministry) intended to revise the Swiss Mining Law before issuing new permits. The applications were deemed legally “frozen”. As such, Aurania believes all rights, title and interest under the permits, have been preserved. To June 30, 2018, Company Management is unaware of any change in the status of the permits.

Last month, Aurania Resources announced that Metron Incorporated of Reston, Virginia, has joined the Lost Cities - Cutucu Project team. Metron will provide data analytic and statistical analysis services to Aurania to help refine its search for the gold mining centres, Logroño de los Caballeros and Sevilla del Oro. These were major gold mines operated by the Spanish in Colonial times. Based on historical records, Aurania Resources believes these mines are positioned within its large, 2,080 square kilometer Project in southeastern Ecuador.

Yesterday, Aurania Resources announced that the stream sediment sampling program, which has now been completed over 50 percent of the Lost Cities - Cutucu Project in southeastern Ecuador, has identified a total of 17 "epithermal" targets for gold and silver. The latest addition to the target list is "Apai". This is an epithermal target near the southern boundary of the Project. The Apai target consists of a number of networks of streams, which contain elevated concentrations of pathfinder elements - naturally-occurring arsenic and antimony, among others - that ususally occur in haloes that enclose epithermal gold-silver systems.

Aurania Resources Ltd. (AUIAF), closed Thursday's trading session at $2.04, up 1.3816%, on 6,675 volume with 17 trades. The average volume for the last 3 months is 11,017 and the stock's 52-week low/high is $1.43499994/$3.04999995.

chart

CannaPowder, Inc. (CAPD)

TeleTrader, Street Insider, Last10k, Wallet Investor, Market Screener, InvestorsHub, Stockhouse and Simply Wall St reported beforehand on CannaPowder, Inc. (CAPD), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

CannaPowder, Inc. is developing innovative nanometric cannabis powders. These are to enable cannabis users, whether for recreational or medicinal purposes, to more efficiently interact with the endocannabinoid mechanism. Nanometric powder is a pioneering drug delivery mechanism that is highly efficient. The Company previously went by the name Smart Energy Solutions, Inc. It changed its name to CannaPowder, Inc. in December of 2017. Established in 1999, CannaPowder has its head office in Tel Aviv, Israel.

Nanometric powders have considerable advantages over non-nanometric powders and plant oils. These include effective production processes and acceptable dosage forms, decreased dosage requirement, improved absorption, bioavailability and efficacy, and relatively long shelf life. Nanometric powders are already being used for other plants by some generic pharmaceutical companies, with different FDA (Food and Drug Administration) approved drugs, and by other industries such as cosmetics, beauty products and others.

The technology that is the foundation CannaPowder’s delivery system was developed at The Hebrew University of Jerusalem, an international leader in academic research and development of medical cannabis, under the leadership of Dr. Shlomo Magdassi, Professor of Chemistry at the Center for Nanoscience and Nanotechnology.

CannaPowder, having verified the technology, entered into an exclusive global license for the process with Yissum Research and Development Company. This is the technology transfer arm of The Hebrew University of Jerusalem.

The Company has engaged Professor Magdassi to continue oversight of its work to commercialize the technology on an industrial scale. In addition, CannaPowder entered into an agreement with Univo Pharmaceutical Ltd., to process cannabis on its behalf. Univo has one of the very few processing licenses issued in Israel.

The technology involves the use of a Nanometric powder formulation consisting of a cannabinoid oil and other materials that are dispersed in water controlled by a number of repeatable parameters. The oil concentration can be increased or decreased in the process and can include permeation enhancers for increasing bioavailability. Moreover, it can be formulated in different pharmaceutical delivery systems including capsules, tablets, creams, as well as aqueous dispersions.

CannaPowder, Inc. (CAPD), closed Thursday's trading session at $1.20, up 18.8119%, on 375 volume with 6 trades. The average volume for the last 3 months is 265 and the stock's 52-week low/high is $0.699999988/$5.00.

chart

Cardiol Therapeutics, Inc. (CRTPF)

Stock Gumshoe, InvestorX, OTC Markets, Cannabis FN, NIC Investors, Stock Target Advisor, Invest Tribune, Market Screener, Investing News, Growstox, and Stockhouse reported previously on Cardiol Therapeutics, Inc. (CRTPF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Cardiol Therapeutics, Inc. (OTCQX-listed) specializes in the research and commercial development of novel drug therapies utilizing proprietary drug-delivery systems. A biotechnology company, it is a leader in the research and commercial development of pharmaceutical CBD (cannabidiol) and targeted therapies for inflammatory diseases. Cardiol is taking advantage of its expertise in pharmaceutical CBD to develop ultra-pure CBD products for commercialization in the billion dollar market for medicinal cannabinoids in Canada. Incorporated in 2017, Cardiol Therapeutics is based in Oakville, Ontario.

Cardiol has a view to expanding into Latin America and Europe. It also has a view to using nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure. The Company is leveraging its expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in three important medical markets.

These include commercializing a line of pharmaceutically-manufactured pure cannabidiol products in the increasing market for medical cannabinoids, developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure; and pursuing an immunotherapeutic program beginning with an innovative cancer immunotherapeutic in combination with cannabinoids for Glioblastoma Multiforme, a Fast Track eligible orphan indication.

Cardiol Therapeutics’ nanotherapeutics are founded on a patented family of biocompatible and biodegradable amphiphilic block co-polymers made from polyethylene glycol (PEG) and polycaprolactone (PCL). PEG and PCL have a long history of safe use in humans. The Company’s proprietary nanoparticles have improved inherent stability and biocompatibility. Moreover, they can be customized to optimize the encapsulation and release characteristics of a broad array of pharmaceuticals.

The Company's lead product is CardiolRx. The design of it is to be the safest and most consistent CBD formulation on the market. CardiolRx is pharmaceutically produced, cGMP certified, and does not contain any THC (Tetrahydrocannabinol). Cardiol Therapeutics plans to commercialize CardiolRx during this year in the billion-dollar market for medicinal cannabinoids in Canada. It is also pursuing market introduction opportunities in Europe and Latin America.

Cardiol Therapeutics is planning a worldwide clinical study of CardiolRx in acute myocarditis. Its acute myocarditis program provides a unique opportunity to build brand awareness in support of this commercial launch. An independent Steering Committee consisting of thought leaders in cardiology from North America and Europe are designing the program. Additionally, Cardiol is developing proprietary nanotechnology to deliver pharmaceutical CBD and other anti-inflammatory drugs directly to sites of inflammation in the heart, which are associated with the development and progression of heart failure.

Cardiol Therapeutics’ President and Chief Executive Officer, Mr. David Elsley, will be presenting at the Canaccord Genuity 39th Annual Growth Conference taking place August 7-8, 2019 at the InterContinental Boston, Massachusetts. Cardiol Therapeutics’ presentation is scheduled for August 8th at 11:30 a.m. EDT. The Company's management is also available for one-on-one meetings.

Cardiol Therapeutics, Inc. (CRTPF), closed Thursday's trading session at $3.80, up 5.5556%, on 6,828 volume with 25 trades. The average volume for the last 3 months is 23,449 and the stock's 52-week low/high is $2.51999998/$10.00.

chart

Drone Aviation Holding Corp. (DRNE)

The Hot Penny Stocks, Zacks, Stockhouse, Street Insider, Otc.Watch, Biz Journals, 4-Traders, Wallet Investor, InvestorsHub, and Market Screener reported previously on Drone Aviation Holding Corp. (DRNE), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Drone Aviation Holding Corp. is a developer of specialized, tethered aerial monitoring and communications platforms serving national defense and homeland security customers. The Company develops and manufactures cost-effective, compact and quickly deployable aerial platforms. These include lighter-than-air aerostats and drones designed to provide government and commercial customers with enhanced surveillance and communication capabilities. OTCQB-listed, Drone Aviation is headquartered in Jacksonville, Florida.

Drone Aviation’s specialized tethered aerial monitoring and communications platforms are for use in applications including intelligence, surveillance and reconnaissance (ISR) and communications. The design of its products are for military and security applications where they can provide secure and reliable aerial monitoring for extended durations. This is while being tethered to the ground through a high strength armored tether.

The Company centers primarily on the development of a tethered aerostat known as the Winch Aerostat Small Platform (WASP). It has been purchased by tier-one customers. These include the U.S. Department of Defense and the Department of Homeland Security. Common applications of WASP include extending network communications and intelligence, surveillance and also reconnaissance.

The Company’s WASP Lite uses the proven fieldability of Drone Aviation’s larger WASP Aerostat System. It offers a smaller footprint for expeditionary missions. WASP Lite can fit in the back of a pickup truck, or on a boat or UTV. In addition, Drone Aviation’s FUSE Tether System is a tether kit for unlimited flight time. It maximizes a customer’s drone investment through achieving safe and reliable operation through ground power.

Pertaining to Drones, the Company has its WATT 200. The design of it is for user friendliness, making it ideal for commercial operators. It also has its WATT 300. The design of it is as a heaver-lift tethered drone created for multi-mission requirements.

In July, Drone Aviation announced that it completed a U.S. Army safety and performance review and delivered numerous WASP Lite aerostat systems to the customer under the $1.1 million award announced in May of this year. The first-of-its-kind, the WASP Lite systems successfully completed extensive customer operational flight safety and performance testing in Jacksonville. They were subsequently shipped to the U.S. Army for transportation to currently deployed ground forces.

Mr. Jay Nussbaum, Chairman and Chief Executive Officer of Drone Aviation, said, “Acceptance testing and delivery of our first production run of WASP Lite systems to the Army is an exciting milestone and we are especially proud that these new systems will be providing critically-needed battlefield communications capabilities for the brave men and women deployed on the ground overseas. I am pleased that we were able to leverage our recent investments in manufacturing capacity and inventory to deliver these products in record time.”

Drone Aviation Holding Corp. (DRNE), closed Thursday's trading session at $0.786, off by 0.253807%, on 1,125 volume with 4 trades. The average volume for the last 3 months is 4,556 and the stock's 52-week low/high is $0.360599994/$2.00.

chart

Precision Optics Corporation, Inc. (PEYE)

Zacks, 4-Traders, GlobeNewswire, Market Screener, PR Newswire, BioSpace, TMX Money, TradingView, Wallet Investor, and Stockopedia reported previously on Precision Optics Corporation, Inc. (PEYE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components. For three decades, the Company has provided state-of -the-art optics and optical systems for medical, biomedical, as well as industrial applications. Its unique medical instrumentation line includes state-of-the-art endoscopes and endocouplers and also custom illumination and imaging products for use in minimally invasive surgical procedures. OTCQB-listed, Precision Optics is headquartered in Gardner, Massachusetts.

The Company’s expertise is providing lenses to sizes as small as 0.2mm in diameter using its proprietary micro-precision™ technology with the quality of ground lenses approaching the cost of gradient index (GRIN) lenses. Precision Optics can design, prototype, and manufacture, under one roof, optical systems and components for imaging of the body's smallest compartments and tissues.

In addition, the Company has mastered the advanced techniques required to manufacture custom designed prisms. With tolerances to .01mm, it can produce a broad array of prisms to meet clients exacting requirements. Precision Optics also provides optical components, optical system design and production of diverse lens and prism products for the defense industry and aerospace industry. As a critical vendor, the Company can assist a client’s optics development efforts from system design through volume optics fabrication and manufacturing.

Furthermore, Precision Optics has been contract manufacturing OEM (original equipment manufacturer) optics components and assemblies for more than 30 years. The Company’s micro optical, micro mechanical, and electro optical assembly services use Precision’s specialized techniques, tools and fixtures to assemble components in the range of 1 millimeter and smaller. Precision Optics fabricates and assembles components, sub-assemblies, as well as complete endoscopic instruments.

In July, Precision Optics announced that it completed the acquisition of certain assets of Ross Optical Industries, Inc., a privately-held company based in El Paso, Texas. This acquisition extends Precision Optics’ product offering to include a broader spectrum of lens and optical system sizes. The acquisition also increases the Company’s presence in the U.S. defense sector.

It also enables the combined Company to take advantage of Precision Optics’ technical proficiency in offering end-to-end solutions, from design through production, to the expansive Ross Optical customer base, increasing its value-add capabilities. Ross Optical Industries provides custom, precision-engineered solutions for OEM applications, specialty standard lenses, micro optics and other hard-to-find optics.

Precision Optics Corporation, Inc. (PEYE), closed Thursday's trading session at $1.26, up 6.7797%, on 23,800 volume with 16 trades. The average volume for the last 3 months is 13,660 and the stock's 52-week low/high is $0.649999976/$1.85000002.

chart

BioVie, Inc. (BIVI)

NetworkNewsWire, Penny Stock Tweets, Stockhouse, Investor Place, Wallmine, Wealth Insider Alert, InvestorsHub, Morningstar, YCharts, EuroInvestor, MarketWatch, GuruFocus, Street Insider, and Simply Wall St reported earlier on BioVie, Inc. (BIVI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. focuses on the discovery, development, and commercialization of unique drug therapies for liver disease. At present,  the clinical-stage Company is centering on commercializing BIV201. This is a novel approach to the treatment of ascites due to chronic liver cirrhosis. OTCQB-listed, BioVie has its corporate headquarters in Beverly, Massachusetts.

The Company states that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. The US Patent and Trademark Office (USPTO) issued US Patent No. 9,655,945 covering BioVie’s new drug candidate BIV201.   

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a major unmet medical need. The Food and Drug Administration (FDA) has never approved any drug specifically for treating ascites.

BIV201 is a continuous infusion of the peptide terlipressin, first undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in about 40 nations for other complications of liver cirrhosis coming up from a similar disease pathway. Terlipressin is not available in the United States. 

BioVie announced in April 2017 that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 could begin. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites due to advanced liver cirrhosis. BioVie also announced in April 2017 the signing of a Cooperative Research and Development Agreement (CRADA). This is to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites because of advanced liver cirrhosis. 

The FDA has granted Fast Track designation for BIV201 (continuous infusion terlipressin), BioVie’s patented Orphan drug candidate. BIV201 is currently undergoing evaluation for the treatment of refractory ascites because of liver cirrhosis in a mid-stage (Phase 2a) U.S. clinical trial.

The FDA has granted Orphan Drug designation to BioVie for terlipressin for the treatment of hepatorenal syndrome (HRS). BioVie earlier secured an Orphan Drug designation for terlipressin for treating ascites. The Company is exploring additional Orphan designation opportunities.

This month, BioVie announced that it completed enrollment in a Phase 2a open-label clinical study of BIV201 (continuous infusion terlipressin) in patients with refractory ascites because of advanced liver cirrhosis.

Patrick Yeramian, MD, BioVie’s Chief Medical Officer, said, “We are pleased to have achieved this important clinical milestone as we continue to develop BIV201 for patients with refractory ascites who are at high risk of deadly complications. What we have learned from this initial study is informing our next clinical trial design. The results will be presented to the FDA in the first half of 2019 and we expect to receive guidance on the BIV201 clinical development plan.”

BioVie, Inc. (BIVI), closed Thursday's trading session at $0.12, up 20.00%, on 51,250 volume with 10 trades. The average volume for the last 3 months is 88,192 and the stock's 52-week low/high is $0.021099999/$0.174999997.

chart

Rezolute, Inc. (RZLT)

Spotlight Growth, Emerging Growth, MarketWatch, Dividend Investor, Market Screener, OTC Markets, Simply Wall St, GuruFocus, Street Insider, Investing Online, The Street, Stockopedia, Morningstar, InvestorsHub, 4-Traders, Barchart, last10k, Stockhouse, YCharts and Wallet Investor reported earlier on Rezolute, Inc. (RZLT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rezolute, Inc. is a clinical stage biopharmaceutical company headquartered in Louisville, Colorado. It specializes in the development of innovative drug therapies for metabolic and orphan diseases. The Company formerly went by the name AntriaBio, Inc. It changed its corporate name to Rezolute, Inc. in December of 2017. Rezolute’s shares trade on the OTC Markets Group’s OTCQB.

Rezolute is advancing a divers pipeline. This pipeline includes RZ358 (Phase 2). This is an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy. In addition, the pipeline includes AB101 (Phase 1). This is a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management through reducing the therapeutic burden for patients and improving compliance.  

The Company’s pipeline also includes a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds. One is RZ402 targeting Diabetic Macular Edema (DME). The other is RZ602 targeting Hereditary Angioedema (HAE), an orphan indication. 

Rezolute and XOMA Corporation have executed a license agreement. The agreement provides Rezolute with the exclusive international rights to develop and commercialize RZ358 (formerly XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication. XOMA is a pioneer in the discovery, development, as well as licensing of therapeutic antibodies. 

RZ358 is a first-in-class fully human monoclonal antibody. It counteracts the effects of elevated insulin via allosteric modulation of the insulin receptor. This makes it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI.

Last month, Rezolute announced that it entered into a $25 million preferred stock purchase agreement with two pharmaceutical companies that have elected to make a strategic investment in Rezolute. The investors include Handok, Inc., and Genexine, Inc., two premier publicly traded South Korean-based pharmaceutical companies. These two have a collective market capitalization of greater than $1.7 billion. With this agreement, each preferred share is priced at $5.00 and automatically converts into shares of Rezolute’s common stock at an implied per share price of $0.22.

Rezolute’s intention is to use the proceeds from this offering to advance its clinical programs. This includes initiating a Phase 2b clinical study for RZ358 in the U.S. and Europe; completing the required toxicology studies for RZ402 to enable the filing of an IND and initiation of clinical studies; and completing an ongoing Phase 1 study for AB101.

Rezolute, Inc. (RZLT), closed Thursday's trading session at $0.47, up 121.5936%, on 1,819 volume with 3 trades. The average volume for the last 3 months is 12,728 and the stock's 52-week low/high is $0.090000003/$0.495999991.

chart

Alltemp, Inc. (LTMP)

MissionIR, Stock Communications Group, Dividend Investor, 4-Traders, InvestorsHub, GuruFocus, The Street, Investors Hangout, Barchart, StockInvest, MarketWatch, Stockhouse, Morningstar, Wallet Investor, Market Screener, and Capital Cube reported earlier on Alltemp, Inc.  (LTMP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Alltemp, Inc. is a developer of proprietary, environmentally-friendly, refrigerant technologies. The Company has developed a proprietary refrigerant technology, called alltemp®. This is a proven replacement for many global refrigerants that have adversely affected the worldwide environment.  Alltemp is based in Westlake Village, California.

alltemp®’s refrigerants are for the commercial and residential markets. alltemp® is the Company’s solution for the replacement of R-407c, R-134a, R-404a, and HCFC-22, known as R-22, but which is quickly being phased out in all developed nations because of environmental concerns over its strong effect on the depletion of the Earth's ozone layer.

  alltemp® refrigerants have broad applications. These range from Heating Ventilation and Air Conditioning (HVAC), to refrigeration and foam insulation, to industrial solvents. alltemp® solutions provide a sustainable, eco-friendly, true drop-in refrigerant. It meets the Montreal/Kyoto Protocols and EPA  (Environmental Protection Agency) standards with the lowest Global Warming Potential for any non-flammable HFC. alltemp®  yields a 27 percent average decrease in kWh,  without loss in capacity.

  Alltemp successfully completed two years of early adopter testing of its alltemp® refrigerant at several Fortune 100 companies' facilities for its Montreal and Kyoto Protocol compliant refrigerant. Furthermore, test results revealed that alltemp® yielded significant average savings in energy consumption. This is while maintaining capacity.

Alltemp announced in January 2018 that it released a new refrigerant alternative for R-404A applications called alltemp® 4. This is a drop-in refrigerant. R-404A has one of the highest GWPs (Global Warming Potential) of any HFC refrigerants. It is quickly being phased out in the European Union (EU) and other developed countries.

Alltemp announced in March 2018 that flashpoint chamber testing conducted by DEKRA Insight confirmed that alltemp® refrigerant has zero flammability. A minimum of 20 different chamber tests in the liquid phase and 20 vapor phase tests, with temperatures as high as 60º C = 140º F, revealed zero flammability and no ignition with alltemp® refrigerant.

Alltemp has its R-410A replacement refrigerant, designated alltemp® H. Like the Company’s other refrigerants, alltemp® H is engineered to use the same anti-corrosive and non-flammable alltemp® core technology that provides major energy efficiencies and meets ASHRAE A1 safety classification standards.

R-410A was designed to replace R-22, which has a substantial environmental impact and Ozone Depletion Potential (ODP). The lower the GWP value, the better the refrigerant is for the environment. R-410A has a Global Warming Potential (GWP) rating of 2,088. Its predecessor R-22 has a GWP rating of 1700.

Alltemp, Inc. (LTMP), closed Thursday's trading session at $0.08, up 58.4158%, on 147,000 volume with 9 trades. The average volume for the last 3 months is 89,293 and the stock's 52-week low/high is $0.029999999/$0.172499999.

chart

Focus Universal, Inc. (FCUV)

Amigo Bulls, Zacks, Simply Wall St, Stockhouse, last10K, Stockopedia, CapitalCube, The Street, Awesome Penny Stocks, Whale Wisdom, Penny Stock Hub, OTC Markets, TradingView, Business Insider, Barchart, Investors Hangout, Financial Content, Street Insider, and Investing News Alerts reported earlier on Focus Universal, Inc. (FCUV),  and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Focus Universal, Inc. is a universal smart instrumentation platform developer and universal smart device manufacturer in the IOT (Internet of Things) market. The Focus Universal technology features a Universal Smart Instrumentation Platform (USIP). The USIP provides an inventive and universal solution for embedded design, industrial control and monitoring. Focus Universal is based in Walnut, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Regarding Focus Universal’s services, the Company offers Large Scale Custom Installation. It can map out any commercial installation requirements and customize a package of devices and sensors to fit any needs.

The above-mentioned USIP uses a mobile device or computer to communicate with smart devices to monitor and control any functions. Consequently, it replaces traditional instrument hardware. The features of the Focus Universal USIP include Universal Customization; Cost Saving; Interoperability; Security; Ease of Use; Scalability; Cloud Instrumentation; and Fast Prototyping.

The smart app interface supports real-time data monitoring. It facilitates instrument control and operation. A wireless data logger (Ubiquitor) acts as a link between the smart device and sensor data acquisition module. The Universal Smart Controller (USC) permits a user to control any device by plugging the sensors into the platform using their smartphone.

In late November, Focus Universal announced that it appointed Mr. Greg Butterfield as an independent Board Member to the Focus Universal team. Mr. Butterfield is a proven entrepreneur in the technology sector and active member in the technology community. He is the Founder and Managing Partner of SageCreek Partners ('SCP') a technology commercialization and consulting firm.

Desheng Wang, Focus Universal Chief Executive Officer, said, ''Mr. Butterfield has a fantastic background in the technology sector that we believe can add great value to our board. He brings expertise in M&A and management experience with both private and public companies that will be a great addition moving forward.''

Focus Universal, Inc. (FCUV), closed Thursday's trading session at $12.25, up 114.9123%, on 400 volume with 4 trades. The average volume for the last 3 months is 89,293 and the stock's 52-week low/high is $0.529999971/$12.25.

chart

Sports Field Holdings, Inc. (SFHI)

Zacks, Real Investment Advice, Wallet Investor, Innovative Marketing, RedChip, Investors Hub, Market Screener, Stockhouse, Stockopedia, Barchart, The Street, Marketwired, Simply Wall St, MarketWatch, and Marketbeat reported on Sports Field Holdings, Inc. (SFHI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Sports Field Holdings, Inc. engages in the design, engineering, and construction of eco-safe athletic facilities. The Company, through its wholly-owned subsidiary, FIRSTFORM, Inc., is a product development, engineering and design-build construction business. Sports Field considers itself a leader in unique playing surfaces that focus on player safety and high performance athletic fields.  Sports Field Holdings is headquartered in Warrenville, Illinois.  

The Company is a product development, engineering, and design-build company, involved in the design, engineering, construction, and construction management of athletic fields and sports complexes. Furthermore, Sports Field Holdings supplies its proprietary, technologically advanced, synthetic turf products and systems to the industry. 

Sports Field Holdings two primary lines of business are construction management of sports facilities and synthetic turf sales. The Company says that these two lines of business can be categorized as design, development, and manufacturing of sports surfacing products and associated pre-engineered construction systems. 

Sports Field Holdings’ FIRSTFORM® subsidiary supplies its proprietary patent-pending products, athletic field systems, and knowledge-based services to the athletic construction industry.  For customers, a FIRSTFORM® Architect will customize their design plan. In addition, a FIRSTFORM® Design Engineer will create their drainage plan. Moreover, a FIRSTFORM® Project Manager will manage the total construction process. 

Sports Field Holdings has its "PrimePlay" crumb rubber-free line of synthetic turf products. Its flagship PrimePlay™ products are available and undergoing installation in athletic facilities throughout the United States.

This past July, Sports Field Holdings, via its wholly-owned subsidiary FIRSTFORM®, announced it signed a contract with Birmingham Community Charter High School to replace the stadium field, resurface the running track and replace the bleachers on the school’s main campus in Los Angeles, California.

Sports Field Holdings’ Chief Executive Officer, Mr. Jeromy Olson, said, “This is an incredibly strategic victory for our company. The Birmingham project represents our first placement in California, which is an enormous financial opportunity due to the importance placed on the safety of athletes and the environment, as well as the fact that drought conditions in California have created a much higher demand for turf fields as compared to other states.

Selected Q2 2018 operational highlights for Sports Field Holdings include being contracted for projects in the two largest school districts in the United States – New York City and Los Angeles. The Company also increased its sales backlog to almost $13M. Furthermore, it renegotiated major service contracts saving tens of thousands in yearly expenses.

Sports Field Holdings, Inc. (SFHI), closed Thursday's trading session at $0.30, up 87.50%, on 100 volume with 1 trade. The average volume for the last 3 months is 1,700 and the stock's 52-week low/high is $0.129999995/$0.649999976.

chart

The Pulse Beverage Corporation (PLSB)

The Green Baron, Greenbackers, Microcap MarketPlace, Wall St Insider Stocks, Ceocast News, SmallCap Network,  FreeRealTime,  PennyStocksV2, BestStocksDaily, Wall Street Resources, RedChip,  Marketbeat.com, HoleinOneStocks.net, and PennyStockClub reported previously on The Pulse Beverage Corporation (PLSB), and today we report on the Company, here at the QualityStocks Daily Newsletter.

The Pulse Beverage Corporation is the maker of Natural Cabana® Lemonades, Limeades, and Coconut Waters. It introduced Natural Cabana® Lemonade in 2012. Since that time,  it has developed a multi-national distribution system through more than 155 distributors in 49 U.S. States, Canada, Mexico, Panama, Bermuda, and Ireland.  OTCQB-listed, The Pulse Beverage Corporation is headquarterered in Northglenn, Colorado.

The Company’s aim is to be one of the market leaders in the development and marketing of nutritional/functional beverage products, which provide real health benefits to a large portion of the population and are convenient and appealing to consumers.

  Pulse Beverage’s business model uses warehouse direct and key accounts. The Company has secured greater than 20,000 listings for its Lemonades and Limeades and over 5,000 listings for its Coconut Waters with regional and national grocery and convenience chain stores.

The Company offers Natural Cabana® Lemonade/Limeade in seven, low-calorie flavors.  Additionally,  Pulse  offers Natural Cabana® Coconut Water in pineapple and natural flavors.

  Pulse Beverage teams up with major retailers. These retailers include Walmart, Albertsons/Safeway, Food Max, Kroger, Stater Bros, Houchens, 7-Eleven, United C-stores, Kmart, and Weis Markets. Major retailers also include King Kullen, WinCo Foods, Price Less Markets, Hy-Vee Supermarket, Gristede's Foods, Toot n Totem, and Travel America.

Last month, Pulse Beverage announced that it acquired international distribution for its Natural Cabana® Coconut Waters in the People’s Republic of China (PRC) via its new U.S. based distribution partner, Better4U Food & Beverage, Inc.

Better4U has distribution in the PRC and consumer demand for more than 15,000 cases per month worth a minimum of $450K per quarter in Net Revenues for Pulse. In this partnership, Better4U pays for the product up front. This eliminates the credit risks for Pulse.

Furthermore, in March, Pulse announced that it acquired international distribution for its Natural Cabana® Lemonades & Limeades in the Republic of China (Taiwan) via Better4U Food & Beverage. Better4U has distribution in Taiwan and consumer demand for more than 6,500 cases per month worth a minimum of $200K per quarter in additional Net Revenues for Pulse.

The Pulse Beverage Corporation (PLSB), closed Thursday's trading session at $0.0002, up 100.00%, on 379,000 volume with 2 trades. The average volume for the last 3 months is 6,773,638 and the stock's 52-week low/high is $0.000099999/$0.001099999.

chart

GeoVax Labs, Inc. (GOVX)

FeedBlitz, SmallCapVoice, M2 Communications, Standout Stocks, Stock Stars, Stockpalooza, PennyTrader.com, DrStockPick, Wall Street Resources, Stock News Now, SmallCapStockPlays, ProActive Capital, IRGnews Alert, PennyOmega, CoolPennyStocks, HotOTC, Penny Performers, and Investor Place reported earlier on GeoVax Labs, Inc. (GOVX), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases utilizing its MVA-VLP vaccine platform. The Company’s vaccine platform supports in vivo production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Established in 2001, GeoVax Labs is headquartered in Smyrna, Georgia.

The Company’s development programs focus on preventive vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. Concerning VLPs, the production of VLPs in the person undergoing vaccination mimics a natural infection, stimulating the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear.

Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the NIH-supported HIV Vaccine Trials Network (HVTN) with financing from the National Institute of Allergy and Infectious Diseases (NIAID). All together, the Company’s HIV vaccines, in varied doses and combinations, have been tested in 500 humans with very encouraging results.

This past July, GeoVax Labs announced that it is collaborating with The Scripps Research Institute (TSRI) in La Jolla, California, and the Institute of Human Virology (IHV) at the University of Maryland Medical School in Baltimore, Maryland, for advanced development of a preventive vaccine against Lassa hemorrhagic fever virus (LASV).

GeoVax Labs earlier announced that its LASV vaccine candidate, GEO-LM01, provided 100 percent protection after single immunization to mice infected with a lethal dose of a LASV reassortant. The intention of this three-way collaboration with TSRI and IHV is to evaluate additional LASV vaccine candidates to clarify involvement of humoral and cellular arms of immunity in protection against LASV infections.

This month, GeoVax Labs announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, delivered an updated presentation of results from studies of the Company’s NS-1 based Zika vaccine. Dr. Guirakhoo delivered the talk, entitled "Development of a Novel Vaccine for Zika," on September 18, 2017 during the 11th Vaccine Congress in San Diego, California.

Dr. Guirakhoo presented research showing that a single intramuscular dose of GeoVax Labs' Zika vaccine gave 100 percent protection in normal mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. The vaccine was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, Colorado with funding by a grant from the CDC.

GeoVax Labs, Inc. (GOVX), closed Thursday's trading session at $0.12, up 27.6596%, on 4,002 volume with 5 trades. The average volume for the last 3 months is 25,735 and the stock's 52-week low/high is $0.093999996/$3.58999991.

chart

The QualityStocks Company Corner

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech Inc. (OTCQB: ETST), a biotech company focused on the nutraceutical and pharmaceutical fields, reported in an SEC 10-K filing that it is prioritizing the marketing of CBD-rich hemp oil and consumer education about the oil’s health and nutritional benefits. ETST markets a complete line of high-grade hemp-CBD oils, hemp-CBD caps and CBD pet oils, with the entire line featuring full-spectrum, pure CBD oils obtained through a super-critical CO2 cold-liquid extraction method (http://nnw.fm/sXqz2).

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed Thursday's trading session at $0.75, up 8.5384%, on 43,200 volume with 33 trades. The average volume for the last 3 months is 52,456 and the stock's 52-week low/high is $0.300999999/$2.45000004.

Recent News

chart

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, this morning announced that its Co-Founder and CEO RJ Tesi, M.D. will present at the Cambridge Healthcare Institute’s Seventh Annual Immuno-Oncology Summit. To view the full press release, visit: http://nnw.fm/6Q32y.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed Thursday's trading session at $8.82, off by 2.5414%, on 22,362 volume with 122 trades. The average volume for the last 3 months is 12,867 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

chart

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) was highlighted today in a publication from Livemoney, examining how, once seen as a taboo for men in China, demands from younger generations have caused a recent boom in the male cosmetics market . Meanwhile, there’s also been a dramatic rise in demand from Chinese pharma groups to also bring in hemp-based products that contain cannabidiol (CBD).

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Thursday's trading session at $5.65, off by 5.6761%, on 1,051,254 volume with 4,008 trades. The average volume for the last 3 months is 1,099,548 and the stock's 52-week low/high is $2.97000002/$8.43999958.

Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International (NASDAQ: YGYI), a leading multi-channel lifestyle company operating in three distinct business segments, this morning announced that its CLR Roasters has hired 35-year industry veteran Omar Peraza to lead the company's food service expansion. To view the full press release, visit: http://nnw.fm/66rZQ.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Thursday's trading session at $4.56, off by 2.7719%, on 63,766 volume with 478 trades. The average volume for the last 3 months is 101,437 and the stock's 52-week low/high is $3.56999993/$16.25.

Recent News

chart

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT)

The QualityStocks Daily Newsletter would like to spotlight Blue Hat Interactive Entertainment Technology (BHAT).

Chinese augmented reality software developer Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) announced on April 30 the finalization of a strategic agreement with Guangdong Family Periodicals Group. Through the partnership, the two enterprises will work toward the development of innovative educational solutions that feature Blue Hat’s innovative technologies, as the company detailed in a press release (http://nnw.fm/b3mtB).

Blue Hat Interactive Entertainment Technology (BHAT) is a cutting-edge creator, developer and operator of popular augmented reality (“AR”) interactive smart toys and educational games in China. Blue Hat’s mobile-connected entertainment platform connects physical items to mobile devices through wireless technologies, creating a unique interactive user experience in various mobile games, interactive educational materials and toys with mobile game features.

Blue Hat designs original toys and games that utilize augmented reality technology, motion capture technology, image recognition technology, voice control, light sense technology, infrared, levitation induction, and other trending scientific technologies to transverse the virtual with reality. Blue Hat creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. This combination provides users with a more natural form of human computer interaction, enhances a user’s perception of reality, and delivers a more immersive entertainment experience.

Proprietary Technology

Founded in 2010, Blue Hat’s proprietary technology, product research and development, marketing channels and brand operation are the cornerstones of the business. Blue Hat focuses on the combination of “online” and “offline” activity and the interaction between “entertainment” and “product” to create a high-tech entertainment platform combining mobile games and AR. With the help of computer graphics, motion capture technology, image recognition technology and visualization technologies, Blue Hat accurately “places” virtual objects into the physical world, creating a new and stimulating visual environment for users.

Blue Hat recently displayed a variety of its sci-tech products at the Guangzhou International Toy Exhibition in China including AR Racer, Elastic Bubbles, AR Space Track, AR Alloy Toy Car, AR Need a Spanking, 5D Animated Magic Aquarium, Bug Travelers, AR Picture Book and other interactive games and smart toys.

The company has multiple products in development including new generations of four primary product lines and two new product lines.

Patents and Copyrights

Blue Hat’s advanced AR technology in interactive entertainment is protected by 178 authorized patents with 44 patents in various stages of the application process.

Another 14 applications for Patent Cooperation Treaty, or PCT, have been filed for international patents. As of March 31, 2019, the company owns 645 copyrights for artwork, 71 registered trademarks and 27 software copyrights.

Sales and Marketing

There has been rapid growth in the toys and games industry in China over the last several years. Total retail sales of toys and games in China soared from RMB 111.8 billion in 2012 to RMB 276.5 billion in 2017 with an average annual growth rate of 19.9% in 2017. Blue Hat believes the company is well positioned with little competition as the toy industry rapidly shifts toward intelligent and interactive toys and games. Retail sales of electronic toys grew at 24% annually in 2017 while that of traditional toys grew at 7%.

In addition to a powerful ecommerce presence, Blue Hat has long-term relationships with partnered distributors that place the company’s AR interactive entertainment products into well-known international retail chains and retail outlets. Blue Hat’s integrated online and offline sales channels include e-commerce giants such as Amazon and Alibaba, retail chain stores and the company’s physical experience store located in Xiamen, China. Blue Hat plans to open or franchise approximately 100 additional stores in China by 2021.

Blue Hat’s community-based platform offers users a highly engaged and interactive community with online communication forums and offline social activities. The company advocates a new model of “teaching through lively activities” and combines AR technology with education, integrating its products into situational teaching, roleplaying and man-machine interaction. This novel educational experience helps realize optimal transformation of information, creating a knowledge and enhancing cognition.

Management

Director and CEO Xiaodong (Sean) Chen has over 20 years of experience creating, developing and producing toys and games related products. Chen earned his EMBA from Renmin University of China and has been chairman of the board of directors and general manager of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

CFO and Director Caifan, who has over 20 years of financial accounting and taxation experience, earned a degree in finance from Hunan University of Finance and Economics. He has served as director, deputy general manager and financial controller of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

Jianyong Cai, chief technology officer and director, has over 35 years of experience in data communication principles, communication network foundation, software engineering, communication network theory and technology and computer network architecture. He holds degrees in data communication principles, communication network foundation and software engineering from University of Science and Technology of China. He has been director, deputy general manager and chief engineer of Fujian Blue Hat Interactive Entertainment Technology Ltd. since January 2010.

Blue Hat Interactive Entertainment Technology (BHAT), closed Thursday's trading session at $3.70, off by 3.1414%, on 166,085 volume with 645 trades. The average volume for the last 3 months is 657,050 and the stock's 52-week low/high is $3.65000009/$6.25.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSXV: RIV) (OTC: CNPOF) is pleased to announce that its portfolio company Radicle Medical Marijuana Inc. ("Radicle") has received approval from Health Canada for its production facility expansion project. This approval effectively doubles Radicle's production footprint, significantly increasing its capacity to 6,000 kilograms per year.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (CNPOF), closed Thursday's trading session at $2.04, off by 2.8335%, on 65,837 volume with 166 trades. The average volume for the last 3 months is 104,726 and the stock's 52-week low/high is $1.75/$7.30155992.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was featured today in the 420 with CNW by CannabisNewsWire. A federal court has ordered the U.S. Drug Enforcement Administration (DEA) to file a written response to a lawsuit filed by a research company seeking for an explanation about the status of the applications submitted to the DEA by entities that expressed interest in growing research-grade marijuana. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how cannabis is quickly becoming one of the most industry-disruptive forces.  Multi-billion-dollar industries are already being uprooted by cannabis, including beverages, alcohol, beer, sports drinks, retailers, pharmaceuticals, tobacco, and the wellness industry, as the cultural renaissance just gets underway. 

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Thursday's trading session at $2.16, off by 4.8458%, on 293,116 volume with 515 trades. The average volume for the last 3 months is 512,471 and the stock's 52-week low/high is $1.60699999/$7.89379978.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Lifestyle-oriented cannabis company Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) today announced the completion of its previously disclosed acquisition of Spring Oaks Greenhouses, Inc., per the terms detailed on July 29, 2019. According to the update, the acquisition brings GGB's ability to operate dispensaries up to 47 across three key states that include Nevada, Massachusetts and Florida. To view the full press release, visit: http://nnw.fm/4ujLK. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how cannabis is quickly becoming one of the most industry-disruptive forces.  Multi-billion-dollar industries are already being uprooted by cannabis, including beverages, alcohol, beer, sports drinks, retailers, pharmaceuticals, tobacco, and the wellness industry, as the cultural renaissance just gets underway. 

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed Thursday's trading session at $1.54, off by 5.2133%, on 638,337 volume with 810 trades. The average volume for the last 3 months is 417,441 and the stock's 52-week low/high is $1.51520001/$5.20499992.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is out to grow the world’s best cannabis and become a leader in the global industry. As Canada’s only coast-to-coast, premium-cannabis producer, SPRWF sees itself at the center of a global shift toward legalizing cannabis. SPRWF is accelerating its growth into the vaporizer market. In June, the company announced an exclusive partnership with PAX Labs (http://nnw.fm/0Zs3T). Also today, the company was featured in the 420 with CNW by CannabisNewsWire. A federal court has ordered the U.S. Drug Enforcement Administration (DEA) to file a written response to a lawsuit filed by a research company seeking for an explanation about the status of the applications submitted to the DEA by entities that expressed interest in growing research-grade marijuana. Additionally, CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announced publication of an article discussing TGODF’s recent merger with Blissco.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Thursday's trading session at $1.0265, off by 0.339806%, on 293,399 volume with 322 trades. The average volume for the last 3 months is 316,637 and the stock's 52-week low/high is $0.850000023/$2.03999996.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

VPR Brands LP (OTC: VPRB) recently announced the availability of its ‘Guide to 2020 U.S. Presidential Candidates on Cannabis Issues’. As voters prepare to gather information about the 2020 elections, VPR Brands released the guide, which will act as a single point of reference on every candidate’s stance on cannabis.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit?www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit?www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit?www.goldlinehemp.com?for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Thursday's trading session at $0.0446, off by 9.5335%, on 82,693 volume with 7 trades. The average volume for the last 3 months is 59,841 and the stock's 52-week low/high is $0.032499998/$0.119999997.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade Inc. (OTC:SGMD) announces the availability of an audio press release titled, “Political Backing, Investor Interest Fuel Kentucky Hemp Boom.” To hear the CannabisNewsAudio version, visit: http://cnw.fm/IEr1L. To read the full editorial, visit: http://cnw.fm/COv56. Also today, NetworkNewsWire released a report on the company detailing the commencement of hemp cultivation in conjunction with Hempistry, Inc., a Kentucky hemp cultivator for which Sugarmade recently announced it had begun to exercise its investment option. To view the full press release, visit: http://nnw.fm/ZfYt1 Additionally, the company was highlighted in a publication from Financialnewsmedia.com, examining how many of the thousands of temporary cannabis business licenses across the state of California could expire before provisional annual licenses can be issued or extensions can be implemented, according to state regulatory data and industry experts.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed Thursday's trading session at $0.0108, off by 8.0851%, on 8,464,662 volume with 124 trades. The average volume for the last 3 months is 3,207,256 and the stock's 52-week low/high is $0.010099999/$0.197500005.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Innovative hemp and cannabis corporation Marijuana Company of America (OTCQB: MCOA) on Wednesday issued an update to its previously disclosed reverse stock split. According to the update, the reverse split is not effective July 31, 2019 as previously stated in the company’s press release dated July 3, 2019 and corresponding Form 8-K filed with the Commission. To view the full press release, visit: http://nnw.fm/s1hLW.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed Thursday's trading session at $0.0054, off by 10.00%, on 19,977,760 volume with 318 trades. The average volume for the last 3 months is 8,685,464 and the stock's 52-week low/high is $0.004499999/$0.039299998.

Recent News

chart

City View Green Holdings Inc. (CSE: CVGR)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR).

City View Green Holdings Inc.'s (CSE: CVGR) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Management

Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR), closed Thursday's trading session at $0.135, up 8.00%, on 53,600 volume. The average volume for the last 3 months is 118,986 and the stock's 52-week low/high is $0.094999998/$0.465000003.

Recent News

chart

Grapefruit Boulevard Investments Inc. (IGNG)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit Boulevard Investments Inc., the wholly owned subsidiary of Imaging3 Inc. (IGNG).

Grapefruit Boulevard Investments Inc., a California corporation (“Grapefruit”), as of May 31, 2019, is a wholly owned subsidiary of Imaging3 Inc. (OTC: IGNG), a Delaware corporation whose shares of $.001 par value common stock are publicly traded on the OTCMarkets OTCQB Market under the symbol “IGNG.” IGNG is subject to the reporting requirements of the Securities Exchange Act of 1934 and files annual and quarterly reports pursuant thereto. Grapefruit holds licenses originally issued by the State of California in January 2018 to both manufacture and distribute cannabis products. Grapefruit’s management now owns a controlling interest in IGNG which now owns 100% of Grapefruit’s outstanding shares. As a result, IGNG’s financial reports will consolidate both IGNG’s and Grapefruit’s balance sheet, statement of operation and statement of cash flows and IGNG and Grapefruit will be operated as a single company. IGNG intends to change its name to Grapefruit and to obtain a more appropriate trading symbol as soon as possible. Hereinafter the combined companies will be referred to as “Grapefruit” or the “Company.”

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds licenses to both manufacture and distribute cannabis products which were originally issued in January 2018 and is fully compliant with all applicable laws and regulations to operate its cannabis manufacturing and distribution businesses.

The company is well-focused on sourcing only the “best of the best” raw cannabis materials to create the highest quality, most-trusted and consistent recreational and medical cannabis products for its customers. Grapefruit is committed to ensuring class-leading quality by rigorously testing the purity and potency of its raw materials throughout the manufacturing process and distribution chain.

Grapefruit owns and operates its fully licensed and compliant ethanol extraction laboratory located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. The company’s extraction lab produces high quality, cannabis-derived distillate, also known as “honey oil,” from cannabis flower and “trim.” THC honey oil is one of base cannabis commodities which serves as the active ingredient in everything from infused edibles and tinctures/creams to the cartridges used in vapes and e-cigarettes. Honey oil often sells on the wholesale marketplace for thousands of dollars per liter, with pricing being dependent on quantity purchased, as well as other market factors such as the availability and cost of the underlying flowers and/or trim.

Grapefruit began its extraction operations in May 2019. Plans are in place to expand its honey oil production through the purchase of additional distillation equipment, which is expected to significantly increase the company’s production capacity by the fourth quarter of 2019. Grapefruit’s extraction lab is fully scalable and expansion will be built-out on a two-acre lot owned by Grapefruit at the Coachillin’ site adjacent to its current manufacturing and distribution operation.

Grapefruit selected the City of Desert Hot Springs for its cannabis extraction laboratory, because the city has created a friendly business environment for cannabis-based manufacturers, including incentives like the absence of taxes on cannabis oil production revenues. This affords Grapefruit a fundamental competitive market advantage over other Honey Oil producers.

The California cannabis regulatory scheme is unique in that it requires all cultivators (cannabis farms) and manufacturers (whether producing oils/distillates, infused edibles, tinctures creams or other cannabis products) to sell their products into the legal cannabis wholesale and retail markets exclusively through licensed distributors such as Grapefruit. Grapefruit initially obtained its California recreational and medicinal cannabis distribution license Jan. 4, 2018. In May 2019, Grapefruit was granted its provisional distribution license which is renewable annually, thereby cementing the regulatory foundation necessary to rapidly expand its distribution business.

Grapefruit’s distribution license affords it a twofold strategic advantage: first, to market and sell its own cannabis product lines to retailers throughout California; and second, to buy and resell bulk cannabis flowers and trim as well as all other legal cannabis products to properly licensed distributors and/or retailers throughout California.

The Coachillin’ Canna-Business Park, home to Grapefruit’s current operating facilities and adjacent two-acre parcel of land, is a 160-acre, self-contained legally mapped compound providing the Company with a fully permitted and serviced physical plant from which Grapefruit intends to establish a leading position in the booming California cannabis sector. The parcel was purchased by the Company prior to the Park’s full development, and the value of the land the Company owns has conservatively since doubled in value to over $2 million. Additional long-term benefits of the Coachillin’ compound include agricultural rates for power, which are currently $0.09 per kilowatt hour; the Park’s deep-water well that fully satisfies its need for water; and security expenses shared by all resident businesses. The Coachillin’ Park’s promoters also plan to position the Park, located only 10 miles north of rapidly growing uptown Palm Springs and less than 15 miles from the site of the Coachella and Stagecoach music festivals as a must-see canna-tourism destination.

Grapefruit’s ultimate goal is to become a vertically integrated, seed-to-sale cannabis and CBD product company serving the California market. Moreover, it plans to roll-out its product lines in other states, such as Nevada, Illinois, Oregon, Colorado and Washington. Grapefruit has plans to build a large, all-inclusive facility that will house a 50,000-square-foot-plus indoor grow canopy, a large extraction laboratory designed to extract both THC and CBD cannabinoids via non-volatile (ethanol) and volatile (butane) processes, a manufacturing space to produce Grapefruit’s vape lines and CBD products, an FDA-certified kitchen for the production of Grapefruit edibles and a distribution facility to sell all products into the entire cannabis market. The indoor grow canopy operation will be outfitted and operated to produce ultra-high-quality flowers and buds, some of which, along with the high-quality trim resulting from cleaning and maintaining the grow, will provide biomass necessary to feed the company’s extraction laboratory. Fueled by this hand cultivated biomass, Grapefruit’s lab will continuously produce pesticide and heavy metal-free world class honey oil to both serve as the active ingredient in all of Grapefruit’s branded and unbranded products and meet the projected ever-growing demand for high quality honey oil in the California market.

Grapefruit’s motto – A High You Can Trust – embodies its philosophy and ethos, reminding consumers of the company’s commitment to manufacturing, procuring and distributing only the highest quality all-natural cannabis flower, concentrates and related products that are free from pesticides, heavy metals and bacteria. Grapefruit will target its products to all recreational cannabis enthusiasts’ as continuous, consistent cannabis products. By relentlessly adhering to these policies Grapefruit intends to become the Titleist of the Cannabis industry, known for unwavering quality and consistency.

Grapefruit is managed by a team of experts possessing the experience, skill and resources required to succeed in the competitive cannabis marketplace. Founded by brothers Bradley Yourist, CEO, and Daniel Yourist, COO, Grapefruit has expanded to become a group of industry professionals sharing a passion for all things cannabis. Both the CEO & COO are attorneys licensed to practice law the State of California who possess expert cannabis licensing and regulatory expertise and experience, which will allow Grapefruit to deftly navigate the ever changing California regulatory landscape and apply for new cannabis licenses at reduced costs when necessary, rather than having to acquire licenses that are often overvalued and/or pay outside counsel to handle such matters.

Grapefruit also has its own line of cannabis-infused concentrates and edibles. Among the brands now in stores or soon to be launched are:

  • Rainbow Dreams is a new lifestyle brand designed specifically for the recreational cannabis marketplace. The Rainbow Dreams brand captures the anything goes party vibe of the 1970s by offering an array of cannabis products, such as a line of vape carts with unique cannabis strains combined with all-natural flavors for a superior no-burn experience. Rainbow Dreams fills an important niche in the marketplace as a top shelf quality product line that is competitively priced.
  • Sugar Stoned, which Grapefruit acquired in the winter of 2018, has always been a popular cannabis edibles brand which terminated operations when recreational cannabis became legal and required a license in California. Grapefruit purchased the Sugar Stoned brand in 2019 and it is now a Grapefruit portfolio brand consisting of a premium quality cannabis-infused gummy line with eight different flavors: blue raspberry, cherry, grape, peach, pineapple, sour apple, strawberry and watermelon. Grapefruit intends to expand the brand in the near future through the release of a variety of infused cookies.

Grapefruit Boulevard Investments Inc. (IGNG), closed Thursday's trading session at $0.0894, up 5.3004%, on 122,721 volume with 21 trades. The average volume for the last 3 months is 152,088 and the stock's 52-week low/high is $0.006095/$0.358999997.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.